The Korean Journal of Cytopathology (대한세포병리학회지)

The Korean Society for Cytopathology (대한세포병리학회)
권호 표지

The Diagnostic Utility of Mesothelial Markers in Distinguishing between Reactive Mesothelial Cell and Adenocarcinoma Cells in Serous Effusions with Cytospin Preparation

장액성 삼출액의 도말 표본에서 반응성 중피세포와 샘암종 세포의 감별에 중피세포 표지자의 유용성

  • Kang, Mi-Sun (Pusan Paik Hospital) ;
  • Choi, Soo-Im (Department of Pathology, Dongrae Paik Hospital Inje University, College of Medicine)
  • 강미선 (부산백병원) ;
  • 최수임 (인제대학교 의과대학 동래백병원 병리과)
  • Published : 2006.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Evaluation of serous effusions can include immunocytochemical stains that differentiate reactive mesothelial cell from adenocarcinoma cell. Among several positive mesothelial cell markers, we used desmin, CK5/6, WT1 and calretinin all known to have high sensitivity and specificity as selective mesothelial cell markers. We studied smears obtained with cytospin from 15 malignant and eight benign effusions. The mesothelial cells were positively stained by desmin, CK5/6, WT1 and calretinin in 60.9%, 29.1%, 26.7% and 56.5%, respectively among 8 benign and 15 malignant effusions; the adenocarcinoma cells were positively stained 6.7%, 13.3%, 1.0% and 0.0%, respectively among 15 malignant effusions. The percentage of positively stained mesothelial cells were somewhat lower for all antibodies compared to the results of previous studies. This was likely due to the differences in preparation methods and fixatives among studies. In conclusion, the use of desmin and calretinin were more valuable than CK5/6 and WT1 for distinguishing between reactive mesothelial cell and adenocarcinoma cells in serous effusion; however, choice of the proper preparation methods and fixatives are also important

Keywords

References

  1. Atkinson BF. Atlas of diagnostic cytopathology. 2nd Ed. Philadelphia: W.B. Saunders. 2003; 205-23
  2. Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol 1996;20:293-325 https://doi.org/10.3109/01913129609016331
  3. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407-14
  4. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223-32 https://doi.org/10.1111/j.1365-2559.2005.02331.x
  5. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-80 https://doi.org/10.1016/j.humpath.2005.01.019
  6. Van Muijen GN, Ruiter DJ, Warnaar SO. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 1987;57:359-69
  7. Chen LM, Lazcano O, Katzmann JA, Kimlinger TK, Li CY. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol 1998;109:712-21 https://doi.org/10.1093/ajcp/109.6.712
  8. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985;121:235-47
  9. Clover J, Oates J, Edwards C. Anti-cytokeratin5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-3 https://doi.org/10.1046/j.1365-2559.1997.2150833.x
  10. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-21 https://doi.org/10.1097/00000478-199810000-00006
  11. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50 https://doi.org/10.1097/00000478-200101000-00004
  12. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-56
  13. Roberts F, McCall AE, Burnett RA. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J Clin Pathol 2001;54:766-70 https://doi.org/10.1136/jcp.54.10.766
  14. Hecht JL, Lee BH, Pinkus JL, Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer 2002;96:105-9 https://doi.org/10.1002/cncr.10482
  15. Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-20
  16. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51 https://doi.org/10.1097/00000478-200308000-00001
  17. Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000;90:312-9 https://doi.org/10.1002/1097-0142(20001025)90:5<312::AID-CNCR8>3.0.CO;2-M
  18. Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61-6 https://doi.org/10.1002/dc.10039
  19. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150-8 https://doi.org/10.1097/00000478-200302000-00002
  20. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7 https://doi.org/10.1097/01.MP.0000056981.16578.C3
  21. Gonzalez-Lois C, Ballestin C, Sotelo MT, Lopez-Rios F, Garcia-Prats MD, Villena V. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-34 https://doi.org/10.1046/j.1365-2559.2001.01157.x
  22. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606 https://doi.org/10.1097/00000478-200004000-00016
  23. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-62 https://doi.org/10.1309/XL6K-8E62-9FLD-V8Q8
  24. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12 https://doi.org/10.1097/00000478-200111000-00008
  25. Gill SA, Meier PA, Kendall BS. Use of desmin immunohistochemistry to distinguish between mesothelial cells and carcinoma in serous fluid cell block preparations. Acta Cytol 2000;44:976-80 https://doi.org/10.1159/000328619
  26. Afify AM, Al-Khafaji BM, Paulino AF, Davila RM. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 2002;10:178-82 https://doi.org/10.1097/00022744-200206000-00014
  27. Kang DY, Son JH. The utility of desmin in differentiation between reactive mesothelial cells, malignant mesothelioma cells and metastatic adenocarcinoma cells in serous effusions. Kor J Cytopathol 2003;14: suppl 1. 45. Abstr https://doi.org/10.1046/j.1365-2303.2003.00041.x
  28. Truong LD, Rangdaeng S, Cagle P, Ro JY, Hawkins H, Font RL. The diagnostic utility of desmin. A study of 584 cases and review of the literature. Am J Clin Pathol 1990; 93:305-14 https://doi.org/10.1093/ajcp/93.3.305
  29. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231-8 https://doi.org/10.1046/j.1365-2559.2003.01686.x
  30. Moll R, Dhouailly D, Sun TT. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;58:129-45 https://doi.org/10.1007/BF02890064
  31. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-12 https://doi.org/10.1038/modpathol.3880018
  32. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10 https://doi.org/10.1038/modpathol.3880483
  33. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-7 https://doi.org/10.1046/j.1365-2559.2000.00770.x
  34. Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004;12:122-6
  35. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996;192:137-47 https://doi.org/10.1016/S0344-0338(96)80208-1
  36. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-46 https://doi.org/10.1097/00000478-199609000-00001
  37. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-16 https://doi.org/10.1046/j.1365-2559.1998.00349.x
  38. Chhieng DC, Yee H, Schaefer D, et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000;90:194-200 https://doi.org/10.1002/1097-0142(20000625)90:3<194::AID-CNCR8>3.0.CO;2-K
  39. Simsir A, Fetsch P, Abati A. Calretinin immunostaining in benign and malignant pleural effusions. Diagn Cytopathol 2001;24:149-52 https://doi.org/10.1002/1097-0339(200102)24:2<149::AID-DC1031>3.0.CO;2-F
  40. Kim BH. Utility of calretinin in distinction between benign reactive mesothelial and carcinoma cells in serous effusions. Kor J Cytopathol 2001;12:89-95
  41. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997;41:1757-61 https://doi.org/10.1159/000333181
  42. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19 https://doi.org/10.1097/00000478-199712000-00003
  43. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-33 https://doi.org/10.1038/sj.mp.4001838
  44. Brockstedt U, Gulyas M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203-9 https://doi.org/10.1309/QHCA-8594-TA7P-0DVQ
  45. Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001;116:709-15 https://doi.org/10.1309/PJ7H-A52V-M3XB-V94Y
  46. Nagel H, Hemmerlein B, Ruschenburg I, Huppe K, Droese M. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. Pathol Res Pract 1998;194:759-64 https://doi.org/10.1016/S0344-0338(98)80065-4
  47. Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60 https://doi.org/10.1002/(SICI)1097-0142(20000225)90:1<55::AID-CNCR8>3.0.CO;2-P
  48. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-5 https://doi.org/10.1002/dc.20203